MedTrace Logo

A Diagnostic Test for Dementia With Lewy Bodies

NCT05479552 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-01-15

No results posted yet for this study

Summary

The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Conditions

  • MCI-AD, Early Stage Alzheimer's Disease
  • MCI-DLB, Early Stage Dementia With Lewy Bodies

Interventions

DIAGNOSTIC_TEST

Syn-One Test

CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • CND Life Sciences

    lead OTHER

Principal Investigators

  • Todd Levine, MD · CND Life Sciences

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-15
Primary Completion
2025-09-28
Completion
2025-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05479552 on ClinicalTrials.gov